In addition to increasing the tumor antigen presentation, ACB1801 induces a deep modification of the immune landscape of B16-F10 tumors characterized by an increase of NK, CD4, and CD8 T cells and decrease of Tregs infiltration in the tumor microenvironment. This evidence concerns the gene CD8A and neoplasm.